Drugs / ROVAZOLAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03859986 | Mar 2019 → Jan 2020 | atopic eczema | Ralexar Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03175354 | Apr 2017 → Jun 2018 | atopic eczema | Ralexar Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROVAZOLAC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297218 ↗ |
| Known as | ALX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03175354 ↗ |
| Modality | Small molecule | — CHEMBL4297218 ↗ |
| Route | Topical | “when applied topically twice daily for 42 days” NCT03175354 ↗ |